Literature DB >> 22427238

Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectum.

Mai Yamauchi1, Teppei Morikawa, Aya Kuchiba, Yu Imamura, Zhi Rong Qian, Reiko Nishihara, Xiaoyun Liao, Levi Waldron, Yujin Hoshida, Curtis Huttenhower, Andrew T Chan, Edward Giovannucci, Charles Fuchs, Shuji Ogino.   

Abstract

OBJECTIVE: Colorectal cancer is typically classified into proximal colon, distal colon and rectal cancer. Tumour genetic and epigenetic features differ by tumour location. Considering a possible role of bowel contents (including microbiome) in carcinogenesis, this study hypothesised that tumour molecular features might gradually change along bowel subsites, rather than change abruptly at splenic flexure.
DESIGN: Utilising 1443 colorectal cancers in two US nationwide prospective cohort studies, the frequencies of molecular features (CpG island methylator phenotype (CIMP), microsatellite instability (MSI), LINE-1 methylation and BRAF, KRAS and PIK3CA mutations) were examined along bowel subsites (rectum, rectosigmoid junction, sigmoid, descending colon, splenic flexure, transverse colon, hepatic flexure, ascending colon and caecum). The linearity and non-linearity of molecular relations along subsites were statistically tested by multivariate logistic or linear regression analysis.
RESULTS: The frequencies of CIMP-high, MSI-high and BRAF mutations gradually increased from the rectum (<2.3%) to ascending colon (36-40%), followed by falls in the caecum (12-22%). By linearity tests, these molecular relations were significantly linear from rectum to ascending colon (p<0.0001), and there was little evidence of non-linearity (p>0.09). Caecal cancers exhibited the highest frequency of KRAS mutations (52% vs 27-35% in other sites; p<0.0001).
CONCLUSIONS: The frequencies of CIMP-high, MSI-high and BRAF mutations in cancer increased gradually along colorectum subsites from the rectum to ascending colon. These novel data challenge the common conception of discrete molecular features of proximal versus distal colorectal cancers, and have a substantial impact on clinical, translational and epidemiology research, which has typically been performed with the dichotomous classification of proximal versus distal tumours.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22427238      PMCID: PMC3345105          DOI: 10.1136/gutjnl-2011-300865

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  57 in total

1.  CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer.

Authors:  Shuji Ogino; Katsuhiko Nosho; Gregory J Kirkner; Takako Kawasaki; Jeffrey A Meyerhardt; Massimo Loda; Edward L Giovannucci; Charles S Fuchs
Journal:  Gut       Date:  2008-10-02       Impact factor: 23.059

2.  Precision and performance characteristics of bisulfite conversion and real-time PCR (MethyLight) for quantitative DNA methylation analysis.

Authors:  Shuji Ogino; Takako Kawasaki; Mohan Brahmandam; Mami Cantor; Gregory J Kirkner; Donna Spiegelman; G Mike Makrigiorgos; Daniel J Weisenberger; Peter W Laird; Massimo Loda; Charles S Fuchs
Journal:  J Mol Diagn       Date:  2006-05       Impact factor: 5.568

3.  Genome-scale analysis of aberrant DNA methylation in colorectal cancer.

Authors:  Toshinori Hinoue; Daniel J Weisenberger; Christopher P E Lange; Hui Shen; Hyang-Min Byun; David Van Den Berg; Simeen Malik; Fei Pan; Houtan Noushmehr; Cornelis M van Dijk; Rob A E M Tollenaar; Peter W Laird
Journal:  Genome Res       Date:  2011-06-09       Impact factor: 9.043

4.  CpG island methylator phenotype (CIMP) of colorectal cancer is best characterised by quantitative DNA methylation analysis and prospective cohort studies.

Authors:  S Ogino; M Cantor; T Kawasaki; M Brahmandam; G J Kirkner; D J Weisenberger; M Campan; P W Laird; M Loda; C S Fuchs
Journal:  Gut       Date:  2006-01-11       Impact factor: 23.059

5.  Methylation tolerance due to an O6-methylguanine DNA methyltransferase (MGMT) field defect in the colonic mucosa: an initiating step in the development of mismatch repair-deficient colorectal cancers.

Authors:  Magali Svrcek; Olivier Buhard; Chrystelle Colas; Florence Coulet; Sylvie Dumont; Illiasse Massaoudi; Amel Lamri; Richard Hamelin; Jacques Cosnes; Carla Oliveira; Raquel Seruca; Marie-Pierre Gaub; Michèle Legrain; Ada Collura; Olivier Lascols; Emmanuel Tiret; Jean-François Fléjou; Alex Duval
Journal:  Gut       Date:  2010-11       Impact factor: 23.059

6.  Association of CTNNB1 (beta-catenin) alterations, body mass index, and physical activity with survival in patients with colorectal cancer.

Authors:  Teppei Morikawa; Aya Kuchiba; Mai Yamauchi; Jeffrey A Meyerhardt; Kaori Shima; Katsuhiko Nosho; Andrew T Chan; Edward Giovannucci; Charles S Fuchs; Shuji Ogino
Journal:  JAMA       Date:  2011-04-27       Impact factor: 56.272

7.  Characterization of rectal, proximal and distal colon cancers based on clinicopathological, molecular and protein profiles.

Authors:  P Minoo; I Zlobec; M Peterson; L Terracciano; A Lugli
Journal:  Int J Oncol       Date:  2010-09       Impact factor: 5.650

8.  LINE-1 hypomethylation is inversely associated with microsatellite instability and CpG island methylator phenotype in colorectal cancer.

Authors:  Shuji Ogino; Takako Kawasaki; Katsuhiko Nosho; Mutsuko Ohnishi; Yuko Suemoto; Gregory J Kirkner; Charles S Fuchs
Journal:  Int J Cancer       Date:  2008-06-15       Impact factor: 7.396

9.  Loss of Rb1 in the gastrointestinal tract of Apc1638N mice promotes tumors of the cecum and proximal colon.

Authors:  Melanie H Kucherlapati; Kan Yang; Kunhua Fan; Mari Kuraguchi; Dmitriy Sonkin; Andrew Rosulek; Martin Lipkin; Roderick T Bronson; Bruce J Aronow; Raju Kucherlapati
Journal:  Proc Natl Acad Sci U S A       Date:  2008-10-01       Impact factor: 11.205

Review 10.  Are there two sides to colorectal cancer?

Authors:  Barry Iacopetta
Journal:  Int J Cancer       Date:  2002-10-10       Impact factor: 7.396

View more
  297 in total

1.  Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803.

Authors:  Shuji Ogino; Kaori Shima; Jeffrey A Meyerhardt; Nadine J McCleary; Kimmie Ng; Donna Hollis; Leonard B Saltz; Robert J Mayer; Paul Schaefer; Renaud Whittom; Alexander Hantel; Al B Benson; Donna Spiegelman; Richard M Goldberg; Monica M Bertagnolli; Charles S Fuchs
Journal:  Clin Cancer Res       Date:  2011-12-06       Impact factor: 12.531

2.  RE: Primary Tumor Location as a Prognostic Factor in Metastatic Colorectal Cancer.

Authors:  Wen-zhuo He; Liang-ping Xia
Journal:  J Natl Cancer Inst       Date:  2015-09       Impact factor: 13.506

Review 3.  Prognostic role of tumor PIK3CA mutation in colorectal cancer: a systematic review and meta-analysis.

Authors:  Z B Mei; C Y Duan; C B Li; L Cui; S Ogino
Journal:  Ann Oncol       Date:  2016-07-19       Impact factor: 32.976

4.  Calcium intake and colon cancer risk subtypes by tumor molecular characteristics.

Authors:  NaNa Keum; Li Liu; Tsuyoshi Hamada; Zhi Rong Qian; Jonathan A Nowak; Yin Cao; Annacarolina da Silva; Keisuke Kosumi; Mingyang Song; Daniel Nevo; Molin Wang; Andrew T Chan; Jeffrey A Meyerhardt; Charles S Fuchs; Kana Wu; Shuji Ogino; Reiko Nishihara; Xuehong Zhang
Journal:  Cancer Causes Control       Date:  2019-04-08       Impact factor: 2.506

5.  KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild-type stage III colon cancers from an adjuvant chemotherapy trial (N0147 alliance).

Authors:  Harry H Yoon; David Tougeron; Qian Shi; Steven R Alberts; Michelle R Mahoney; Garth D Nelson; Suresh G Nair; Stephen N Thibodeau; Richard M Goldberg; Daniel J Sargent; Frank A Sinicrope
Journal:  Clin Cancer Res       Date:  2014-03-31       Impact factor: 12.531

6.  Fusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis.

Authors:  Kosuke Mima; Reiko Nishihara; Zhi Rong Qian; Yin Cao; Yasutaka Sukawa; Jonathan A Nowak; Juhong Yang; Ruoxu Dou; Yohei Masugi; Mingyang Song; Aleksandar D Kostic; Marios Giannakis; Susan Bullman; Danny A Milner; Hideo Baba; Edward L Giovannucci; Levi A Garraway; Gordon J Freeman; Glenn Dranoff; Wendy S Garrett; Curtis Huttenhower; Matthew Meyerson; Jeffrey A Meyerhardt; Andrew T Chan; Charles S Fuchs; Shuji Ogino
Journal:  Gut       Date:  2015-08-26       Impact factor: 23.059

Review 7.  Aspirin and colorectal cancer: back to the future.

Authors:  David Tougeron; Dan Sha; Sashidhar Manthravadi; Frank A Sinicrope
Journal:  Clin Cancer Res       Date:  2013-12-10       Impact factor: 12.531

8.  Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival.

Authors:  Xiaoyun Liao; Paul Lochhead; Reiko Nishihara; Teppei Morikawa; Aya Kuchiba; Mai Yamauchi; Yu Imamura; Zhi Rong Qian; Yoshifumi Baba; Kaori Shima; Ruifang Sun; Katsuhiko Nosho; Jeffrey A Meyerhardt; Edward Giovannucci; Charles S Fuchs; Andrew T Chan; Shuji Ogino
Journal:  N Engl J Med       Date:  2012-10-25       Impact factor: 91.245

9.  Phospholipase A2G1B polymorphisms and risk of colorectal neoplasia.

Authors:  Clare Abbenhardt; Elizabeth M Poole; Richard J Kulmacz; Liren Xiao; Karen Curtin; Rachel L Galbraith; David Duggan; Li Hsu; Karen W Makar; Bette J Caan; Lisel Koepl; Robert W Owen; Dominique Scherer; Christopher S Carlson; John D Potter; Martha L Slattery; Cornelia M Ulrich
Journal:  Int J Mol Epidemiol Genet       Date:  2013-09-12

10.  Risk Factor Profiles Differ for Cancers of Different Regions of the Colorectum.

Authors:  Liang Wang; Chun-Han Lo; Xiaosheng He; Dong Hang; Molin Wang; Kana Wu; Andrew T Chan; Shuji Ogino; Edward L Giovannucci; Mingyang Song
Journal:  Gastroenterology       Date:  2020-04-01       Impact factor: 22.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.